Gilde Healthcare Partners awarded European Venture Fundraising of the year - Gilde Healthcare

Gilde Healthcare Partners awarded European Venture Fundraising of the year

11. Februar 2008

Utrecht – Gilde Healthcare Partners, a rapidly growing European venture capital firm, has received the Venture Fundraising of the Year Award from the European Venture Capital Journal. The Award was for the successful closing of Gilde Healthcare II (GHC II), its EUR 150 million venture fund, in 2007. The original target for GHC II was EUR 125 million.

GHC II is one of the largest venture funds raised to invest in European healthcare opportunities. GHC II was backed by current investors in Gilde Healthcare Funds, who were joined by a small select group of new investors. Investors were attracted by Gilde Healthcare Partners’ excellent investment track record which has seen it achieve six successful exits in the past two years.
 
Gilde Healthcare Partners invests in strong professional management teams developing therapeutics, diagnostics, medical devices and enabling technologies. Gilde creates significant value for both its investors and the driven entrepreneurs it backs by selectively investing in companies with well thought-out business models. The fund invests at all stages of a company’s development from seed stage to pre-IPO rounds. Gilde’s investments range from EUR 1 million up to EUR 15 million per investee company after all private rounds of financing. 
Founded in 2000, Gilde Healthcare Partners is headquartered in Utrecht, The Netherlands with representatives in London and Madrid. Gilde Healthcare Partners currently has over EUR 275 million (USD 400 million) under management. Gilde is an ambitious builder of healthcare businesses across Europe. Companies that Gilde Healthcare Partners has pro-actively supported span all aspects of healthcare and include Ablynx (Belgium), Agendia (Netherlands), AMT (Netherlands), Ascendis Pharma (Denmark), Chroma Therapeutics (UK), Glycart (Switzerland), Innate Pharma (France), Santaris Pharma (Denmark) and Symphogen (Denmark). For a full list of Gilde’s portfolio companies please visit the website.

Gilde Healthcare II is supported by the European Communities Growth and Employment Initiative, MAP – ETF Start up Facility

Gilde Healthcare company CatalYm announces leadership changes to accelerate visugromab late-stage clinical development

Gilde Healthcare company CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced changes to its executive leadership team to support its next stage of growth. The appointments of Clinton Musil as Chief...
15. September 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor...
10. September 2025

Gilde Healthcare ernennt Dr. Christian Stark zum Group CEO ihrer global operierenden Medizintechnikgruppe

Die Medizintechnikgruppe, zu der zwei Hersteller chirurgischer Instrumente aus der Region Tuttlingen gehören, Koscher & Würtz und Christian Diener, hat Dr. Christian Stark mit Wirkung zum 1. September 2025 zum Chief Executive Officer (CEO) berufen....
3. September 2025